ReviewCardio-oncology (London, England)2025
Cardiovascular impacts of combination cancer therapies in Africa: challenges and solutions.
Review in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Africa, deaths from non-infectious causes, including cancer, have been rising. In 2022, over a million new cancer cases were reported, and projections indicate that this number could double by 2040 without significant interventions. To improve cancer management, combination treatments often including systemic therapies, radiotherapy, and surgery are employed, however, they pose the risk of cardiotoxicity. Given the growing burden of cancer and the associated cardiovascular complications, it is essential to evaluate the cardiovascular outcomes of combination cancer therapies in African populations, identify challenges faced by healthcare systems, and propose strategies to mitigate these risks. MAIN BODY: Several anti-cancer agents, including anthracyclines, HER2 inhibitors, immune checkpoint inhibitor myocarditis, VEGF inhibitors, 5-fluorouracil, etc., have been linked to cardiovascular complications. These include left ventricular dysfunction, immune myocarditis, coronary spasms, and oxidative stress-induced cardiomyocyte death amongst others. The field of cardio-oncology has emerged to address these risks and improve patient outcomes. African health systems face unique challenges in managing cardiovascular risks associated with cancer therapies. These include delayed diagnosis and limited screening, resource constraints, underrepresentation in clinical trials, comorbidities, and socioeconomic barriers. These factors hinder early detection and management of cardiovascular complications, exacerbating the burden of treatment-related morbidity and mortality.
conclusionAs the burden of cancer continues to rise in Africa, addressing cardiovascular complications associated with cancer therapies is critical. Strengthening cardio-oncology programs, improving early screening, and increasing access to cardiovascular care within oncology settings are essential steps toward better patient outcomes. By addressing existing gaps and resource limitations, African healthcare systems can enhance cancer treatment while minimizing the attending cardiovascular risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.